{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:38:53Z","timestamp":1773031133344,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,11,10]],"date-time":"2004-11-10T00:00:00Z","timestamp":1100044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:\u2002<\/jats:bold>\n                    The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese hypertensive patients, with a specific attention to cardiovascular effects and to side effects because of this treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Patients were enrolled, evaluated and followed at three Italian Centres of Internal Medicine. We evaluated 115 obese and hypertensive patients. (55 males and 60 females; 26 males and 29 females, aged 50\u2003\u00b1\u20034 with orlistat; 28 males and 30 females, aged 51\u2003\u00b1\u20035 with sibutramine). All patients took antihypertensive therapy for at least 6\u2003months before the study. We administered orlistat or sibutramine in a randomized, controlled, double\u2010blind clinical study. We evaluated anthropometric variables, blood pressure and heart rate (HR) during 12\u2003months of this treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    A total of 113 completed the 4\u2003weeks with controlled energy diet and were randomized to double\u2010blind treatment with orlistat (n\u2003=\u200355) or sibutramine (n\u2003=\u200358). Significant body mass index (BMI) improvement was present after 6 (p\u2003&lt;\u20030.05), 9 (p\u2003&lt;\u20030.02), and 12 (p\u2003&lt;\u20030.01) months in both groups, and body weight (BW) improvement was obtained after 9 (p\u2003&lt;\u20030.05) and 12 (p\u2003&lt;\u20030.02) months in both groups. Significant waist circumference (WC), hip circumference (HC) and waist\/hip ratio (W\/H ratio) improvement was observed after 12\u2003months (p\u2003&lt;\u20030.05, respectively) in both groups. Significant systolic blood pressure (SBP) and diastolic blood pressure (DBP) improvement (p\u2003&lt;\u20030.05) was present in orlistat group after 12\u2003months. Lipid profile [total cholesterol (TC), low\u2010density lipoprotein\u2010cholesterol (LDL\u2010C) and triglycerides] reduction (p\u2003&lt;\u20030.05, respectively) was observed in orlistat group and triglyceride reduction (p\u2003&lt;\u20030.05) in sibutramine group after 12\u2003months. No significant change was observed in sibutramine group during the study. No significant HR variation was obtained during the study in both groups. Of the 109 patients who completed the study, 48.1% of patients in the orlistat group and 17.5% of patients in the sibutramine group had side effects (p\u2003&lt;\u20030.05 vs. orlistat group). Side\u2010effect profiles were different in the two treatment groups. All orlistat side effects were gastrointestinal events. Sibutramine caused an increase in blood pressure (both SBP and DBP) in two patients, but it has been controlled by antihypertensive treatment. The vitamin changes were small and all mean vitamin and \u03b2\u2010carotene values stayed within reference ranges. No patients required vitamin supplementation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    Both orlistat and sibutramine are effective on anthropometric variables during the 12\u2010month treatment; in our sample, orlistat has been associated to a mild reduction in blood pressure, while sibutramine assumption has not be associated to any cardiovascular effect and was generically better tolerated than orlistat.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2004.00372.x","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T05:50:54Z","timestamp":1103694654000},"page":"47-55","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients"],"prefix":"10.1111","volume":"7","author":[{"given":"G.","family":"Derosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F. G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Murdolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. N.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bertone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,11,10]]},"reference":[{"issue":"3","key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ptj\/83.3.276","article-title":"Obesity: overview of prevalence, etiology, and treatment","volume":"83","author":"Racette SB","year":"2003","journal-title":"Phys Ther"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1079\/PHN2001136"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.204"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.12.1711"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/beem.2002.0231"},{"issue":"2","key":"e_1_2_5_7_2","first-page":"174","volume":"2","author":"Wong NN","year":"2000","journal-title":"Orlistat Heart Dis"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000204200908"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C122"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90009-9"},{"key":"e_1_2_5_11_2","first-page":"151","article-title":"1999 WHO\/ISH guidelines for the management of hypertension","volume":"17","author":"WHO\/ISH Mild Hypertension Liaison Committee","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_5_12_2","first-page":"121","article-title":"Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II)","volume":"15","author":"Klose S","year":"1978","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-091304-6.50036-7"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103182"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald WT","year":"1972","journal-title":"Clin Chem"},{"key":"e_1_2_5_16_2","volume-title":"Statistical Principles in Experimental Design","author":"Winer BJ","year":"1971"},{"issue":"3","key":"e_1_2_5_17_2","first-page":"123","article-title":"Medical management of obesity","volume":"13","author":"Kushner RF","year":"2002","journal-title":"Semin Gastrointest Dis"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0095-4543(01)00009-4"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-200209000-00004"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.235"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1996.tb00544.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2002.00181.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(02)80066-2"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80070-X"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200209000-00034"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200211000-00026"},{"issue":"10","key":"e_1_2_5_27_2","first-page":"1307","article-title":"Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias","volume":"166","author":"Wooltorton E","year":"2002","journal-title":"CMAJ"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000036370.31856.73"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802218"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001299"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001298"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789X.2003.00083.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2004.00372.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2004.00372.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:02:26Z","timestamp":1761876146000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2004.00372.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1463-1326.2004.00372.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2004.00372.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,10]]}}}